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Abstract
Background: Although sedation is often required for agitated patients undergoing noninvasive ventilation (NIV),
reports on its practical use have been few. This study aimed to evaluate the efficacy and safety of sedation for
agitated patients undergoing NIV in clinical practice in a single hospital.
Methods: We retrospectively reviewed sedated patients who received NIV due to acute respiratory failure from May
2007 to May 2012. Sedation level was controlled according to the Richmond Agitation Sedation Scale (RASS). Clinical
background, sedatives, failure rate of sedation, and complications were evaluated by 1) sedative methods (intermittent
only, switched to continuous, or initially continuous) and 2) code status (do-not-intubate [DNI] or non-DNI).
Results: Of 3506 patients who received NIV, 120 (3.4 %) consecutive patients were analyzed. Sedation was performed
only intermittently in 72 (60 %) patients, was switched to continuously in 37 (31 %) and was applied only continuously in
11 (9 %). Underlying diseases in 48 % were acute respiratory distress syndrome/acute lung injury/severe pneumonia or
acute exacerbation of interstitial pneumonia. In non-DNI patients (n = 39), no patient required intubation due to
agitation with continuous sedation, and in DNI patients (n = 81), 96 % of patients could continue NIV treatment. PaCO2
level changes (6.7 ± 15.1 mmHg vs. -2.0 ± 7.7 mmHg, P = 0.028) and mortality in DNI patients (81 % vs. 57 %, P = 0.020)
were significantly greater in the continuous use group than in the intermittent use group.
Conclusions: According to RASS scores, sedation during NIV in proficient hospitals may be favorably used to potentially
avoid NIV failure in agitated patients, even in those having diseases with poor evidence of the usefulness of NIV.
However, with continuous use, we must be aware of an increased hypercapnic state and the possibility of increased
mortality. Larger controlled studies are needed to better clarify the role of sedation in improving NIV outcomes in
intolerant patients.
Keywords: Continuous sedation, Intermittent sedation, Noninvasive ventilation, Agitation, Richmond Agitation
Sedation Scale
Background
Noninvasive ventilation (NIV) for acute respiratory
failure is widely used; however, it is sometimes difficult
to continue due to mask intolerance or inadequate co-
operation. Antonelli et al. reported that 9 % of NIV
users for acute respiratory failure had to be intubated
for such reasons [1], and Carlucci et al. reported that
the discontinuation rate of NIV due to patients’ refusal
was up to 22 % [2]. Although NIV usage is not strictly
indicated for agitated or uncooperative patients [3, 4],
a questionnaire to pulmonologists and intensivists
showed that 85 % of such patients had been sedated
while under NIV, with 30 % receiving continuous sed-
ation, suggesting its usefulness in clinical practice [5].
The efficacy of sedatives for agitated patients with
acute respiratory failure undergoing NIV was reported
[3, 6–10]. However, such patients usually had specific
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diseases with strong proven evidence of NIV’s useful-
ness and were treated in the ICU. In clinical practice,
patients undergoing NIV treatment did not always
have such diseases or were not always treated in an
ICU.
In clinical practice, NIV introduction depends not only
on underlying diseases but also on social conditions such
as do-not-intubate (DNI) status. Therefore, NIV may be
introduced to patients having diseases with little evi-
dence of its usefulness. We previously reported the
efficacy of NIV for life-threatening acute exacerbation
of interstitial pneumonia or asthma attack [11, 12],
for which the evidence level for its usefulness was
not high [3].
We hypothesized that we could control agitated pa-
tients with sedation without severe complications re-
gardless of evidence of NIV’s usefulness for their
underlying diseases. Therefore, we retrospectively evalu-
ated the efficacy and safety of sedation that was used
intermittently or continuously for agitated patients dur-
ing NIV treatment in clinical practice.
Methods
Patients
Our hospital is a 700-bed tertiary care center that plays
a central role in treating emergency patients in the sur-
rounding area. Among consecutive patients over 16 years
old who underwent continuous NIV due to acute re-
spiratory failure from May 2007 to May 2012, we retro-
spectively evaluated patients who received sedatives for
agitation during NIV.
We assigned patients to 3 groups; one group received
sedatives only intermittently (intermittent only), a sec-
ond group was switched to continuous sedation after
intermittent sedation (switched to continuous) and the
third group was initially sedated continuously (initially
continuous). According to code status, we also classified
patients into non-DNI and DNI groups. Patients in
the non-DNI group were intubated and mechanically
ventilated if control was not achieved by NIV, while
patients in the DNI group were continuously con-
trolled by NIV and were not intubated even if con-
sciousness deteriorated following sedation or their
conditions became critical. Code status of neurologic-
ally incompetent patients was determined by discus-
sion with relatives. When patients or their families did
not want ventilation to be provided (including NIV) or
their baseline status was difficult to maintain with
NIV, we suggested that ventilation not be applied from
the viewpoint of ethics.
This study was approved by our institutional review
board (Institutional Review Board of Kobe City Medical
Center General Hospital; 1304–1), and informed consent
was waived.
Noninvasive ventilation
NIV was started when 1) SpO2 was <90 % despite inhal-
ation of oxygen >10 l/min via reservoir mask; 2) PaCO2
levels were >45 mmHg with acute respiratory acidosis;
or 3) patients had signs of respiratory distress, including
a respiratory rate >24 and increased accessory respira-
tory muscle use. Patients were managed with NIV in the
ICU, emergency ward, or general ward by expert respira-
tory staff. Patients in a general ward were put in large
separated rooms for intensive care and monitored 24 h
per day. NIV was performed with a Drager ventilator
(Carina; Drager, Lübeck, Germany) or Philips ventilator
(Respironics V60 or Respironics BiPAP Vision; Philips,
Andover, MA, USA) with the pressure support ventila-
tion (PSV) mode or continuous positive airway pressure
(CPAP) mode via a full face mask. The ventilator setting
and selection of either the CPAP or PSV mode were gen-
erally determined based on the criteria for initiation of
NIV described above. The PSV was selected if a patient
met criterion 2) and/or 3), but if a patient had only hypox-
emia and met criterion 1), we selected the CPAP mode.
For the PSV mode, the initial setting was a respiratory rate
of 12 breaths/min, inspiratory positive airway pressure of
10 cm H2O, and expiratory positive airway pressure of
4 cm H2O. For the CPAP mode, the first setting was a
positive end expiratory pressure of 8 cm H2O. The FiO2
was adjusted to keep the SpO2 > 90 %. After the start of
NIV treatment, NIV settings were modified by physicians
proficient in NIV treatment according to each patient’s
condition. At first NIV treatment was performed all day.
However, we discontinued NIV treatment in the cases that
met all the following criteria: 1) SpO2 was >90 % with the
inhalation of oxygen <10 l/min via reservoir mask; 2)
PaCO2 levels were <45 mmHg or patients did not suffer
acute respiratory acidosis; and 3) patients had no signs of
respiratory distress, including a respiratory rate >24 and in-
creased accessory respiratory muscle use. When NIV treat-
ment was not needed consecutively for 12 h, NIV
treatment was considered to be finished.
Sedatives
For intermittent use, risperidone or haloperidol was usually
administered every 30–60 min by either a single dose or
double dose (Table 1). For continuous use, either dexmede-
tomidine, midazolam, or propofol was the initial choice.
Physicians in this hospital preferred to use a short-acting
drug or a drug with a minimal respiratory depressant effect.
When despite sedation dyspnea could not be controlled, we
used morphine or fentanyl to alleviate the dyspnea.
Criteria for the beginning of sedation and administration
of sedatives
When NIV was started according to the criteria de-
scribed above, we used the Richmond Agitation Sedation
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Scale (RASS) [13] as an index of sedation for con-
trolling agitation. Sedatives were administered when
patients could not continue NIV due to agitation, and
generally, +1 or more on the RASS was defined as an in-
dication to administer sedation. Patients were most often
managed between −2 and 0 on the RASS during sedation.
Usually, sedation was initiated intermittently and if the
target sedation level was not achieved, we began continu-
ous administration. However, continuous sedation was
introduced initially when physicians judged that intermit-
tent sedation would not be sufficient to control agitation.
At that time the attending physicians set the target range
for the RASS, which was most often measured by med-
ical staff. When the RASS deviated from the established
range, the infusion rate was adjusted as shown in Table 1.
When good control was not achieved with the first seda-
tive, another was added.
Outcome measures
We examined the clinical background, kinds of sedatives
used, failure rate of sedation, and complications. All clin-
ical and laboratory data were obtained from medical
records. To assess severity of the respiratory failure, the
PaO2/FiO2 (P/F) ratio at the initiation of NIV was calcu-
lated. Decision for intubation was left to attending physi-
cians based on lack of control of agitation or progressive
respiratory deterioration. In this study, failure of sed-
ation consisted of the need for withdrawal of NIV be-
cause of absolute intolerance by patients despite the
maximized analgo-sedative strategy. That is, in the non-
DNI group, failure of sedation was declared when a pa-
tient was intubated due to agitation in spite of sedation,
and failure of sedation in the DNI group was declared
when NIV treatment could not be continued due to agi-
tation. A RASS score of −4 or −5 indicated oversedation.
Physiologic values were monitored and the RASS score,
respiratory rate, heart rate, and blood pressure were
checked before sedation and as closely as possible to
2 h, 6 h, and 24 h after the start of sedation. Arterial
blood gas changes during 24 h following the initiation of
sedation were also checked.
In measuring outcome, we compared differences in
clinical background, 30-day mortality, and failure rate of
sedation between the intermittent use group (intermittent
only) and continuous use group (switched to continuous
plus initially continuous groups combined) separately in
the DNI and non-DNI groups.
Statistical analysis
Continuous variables are expressed as mean ± standard
deviation unless stated otherwise and were compared
using the Mann–Whitney test. Categorical variables were
compared using a chi-squared test or Fisher’s exact test, as
appropriate. A P-value <0.05 was deemed statistically sig-
nificant. All statistical analyses were performed using JMP
8.0.2 software (SAS Institute Inc., Cary, NC, USA).
Results
Study population
From May 2007 to May 2012, 3506 consecutive patients
received NIV due to acute respiratory failure. Of these,
120 (3.4 %, non-DNI = 39; DNI = 81) patients were given
sedatives to control agitation during NIV. Figure 1
shows the number of patients and method of adminis-
tration of sedatives. Finally, sedation was performed only
intermittently in 72 (60 %) patients, switched to continu-
ously in 37 (31 %) and provided only continuously in 11
(9 %). The reasons for poor tolerance of NIV were mostly
mask discomfort, pressure discomfort, or the combination
of the two. Most expressions of poor tolerance occurred
immediately after the start of NIV treatment.
Underlying diseases
Table 2 shows underlying diseases of study patients. Of the
120 patients, 58 (48 %) had acute respiratory distress syn-
drome (ARDS)/acute lung injury (ALI)/severe pneumonia
or acute exacerbation of interstitial pneumonia, diseases
for which evidence of the usefulness of NIV was poor [3].
Sedatives
Table 3 shows the prescribed sedatives. Twenty-four
(50 %) patients received a single drug and the remaining
patients received more than one drug for continuous
use. With the exception of risperidone or haloperidol,
hydroxyzine, quetiapine, diazepam or perospirone was
used intermittently.
Baseline characteristics
Baseline characteristics of the non-DNI and DNI groups
in the intermittent use group or continuous use group
Table 1 Initial dose and increasing and decreasing dose of
each sedative drug
Drug Initial dose Increasing and
decreasing dose
Risperidone 0.5 mg perorally
Haloperidol 2.5–5 mg by intravenous infusion
Dexmedetomidine 0.2 μg/kg/h by continuous
intravenous infusion
0.1 μg/kg/h
Midazolam 0.03 mg/kg/h by continuous
intravenous infusion
0.01 mg/kg/h
Propofol 0.3 mg/kg/h by continuous
intravenous infusion
0.1 mg/kg/h
Morphine 0.02 mg/kg/h by continuous
subcutaneous infusion
0.01 mg/kg/h
Fentanyl 0.05–0.1 μg/kg/h by continuous
subcutaneous infusion
0.05 μg/kg/h
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Fig. 1 Number of patients at each stage of analysis and method of administration sedative drugs. Patients were categorized into the non-DNI
group and DNI group. NIV, noninvasive ventilation; DNI, do-not-intubate. *: 4 patients used sedation for pain and 2 for convulsion
Table 2 Underlying diseases in each patient group
Evidence levela Intermittent only (n = 72) Switched to continuous (n = 37) Initially continuous (n = 11) Total
Non-DNI (n= 28) DNI (n= 44) Non-DNI (n= 8) DNI (n= 29) Non-DNI (n= 3) DNI (n = 8) n = 120
Acute exacerbation of
COPD
1 (favorable) 0 (0 %) 4 (9 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 4 (3 %)
Cardiogenic pulmonary
edema




1 (favorable) 5 (18 %) 3 (7 %) 3 (38 %) 4 (14 %) 2 (67 %) 0 (0 %) 17 (14 %)
Bronchial asthma 3 (favorable) 1 (4 %) 1 (2 %) 1 (13 %) 0 (0 %) 0 (0 %) 0 (0 %) 3 (3 %)
ARDS/ALI/severe pneumonia 2 or 3 (caution) 5 (18 %) 20 (45 %) 1 (13 %) 9 (31 %) 1 (33 %) 3 (38 %) 39 (33 %)
Acute exacerbation of
interstitial pneumonia
4 (caution) 2 (7 %) 4 (9 %) 1 (13 %) 9 (31 %) 0 (0 %) 3 (38 %) 19 (16 %)
Sequela of pulmonary
tuberculosis
NA 0 (0 %) 4 (9 %) 0 (0 %) 2 (7 %) 0 (0 %) 0 (0 %) 6 (5 %)
Othersb NA 4 (14 %) 6 (14 %) 1 (13 %) 0 (0 %) 0 (0 %) 1 (13 %) 12 (10 %)
n number of patients, DNI do-not-intubate, ARDS acute respiratory distress syndrome, ALI acute lung injury, NA not available
aevidence level from previous report 2; Each disease is classified as favorable or caution according to evidence level of use of NIV; 1 is the highest evidence level
and 4 is the lowest
bincludes hepatogenic pleural effusion, carcinomatous lymphangitis, pulmonary embolism, reexpansion pulmonary edema, and cryptogenic organizing pneumonia
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are shown in Table 4. Within the non-DNI group,
patients in the continuous use group (n = 11) were
significantly younger than in the intermittent use group
(n = 28) and baseline severity assessed by the P/F ratio
did not differ between the two groups.
In the DNI group, patients in the continuous use
group (n = 37) were also significantly younger than in
the intermittent use group (n = 44). The proportion of
patients with hypercapnia was significantly higher in the
intermittent use group than in the continuous use
group. P/F ratio was significantly lower in the continu-
ous use group.
Thirty-four of the 109 (31 %) non-DNI or DNI pa-
tients in the initially intermittent group were managed
in a general ward at first. Later 2 of these patients were
transferred to the ICU for the initiation of continuous
sedation with intensive monitoring.
Mortality and failure rate of sedation
Mortality rate of the study participants and failure rate
of sedation are shown in Table 5.
In non-DNI patients, 30-day mortality and the total
intubation rate did not differ significantly between the
intermittent use and continuous use groups. No patient
in the continuous use group required intubation due to
agitation while 2 patients (7 %) in the intermittent use
group required intubation due to sedation failure. After
all, 2 of 36 patients with initially intermittent sedation
were intubated without switching to continuous sedation
due to their uncontrolled agitation.
Among DNI patients, 30-day mortality was higher in
the continuous use group. Two of the 44 patients (5 %)
in the intermittent use group and 1 of the 37 patients
(3 %) in the continuous use group could not continue
NIV due to persistent agitation; therefore, 78 of 81 (96 %)
Table 3 Sedative drugs administered to each patient group
Intermittent only (n = 72) Switched to continuous (n = 37) Initially continuous (n = 11) Total
Non-DNI (n = 28) DNI (n = 44) Non-DNI (n = 8) DNI (n = 29) Non-DNI (n = 3) DNI (n = 8) n = 120
Risperidone 13 (46 %) 20 (45 %) 5 (63 %) 13 (45 %) 51 (43 %)
Haloperidol 20 (71 %) 35 (80 %) 8 (100 %) 24 (83 %) 87 (73 %)
Others 0 (0 %) 10 (23 %) 1 (13 %) 0 (0 %) 11 (9 %)
Dexmedetomidine 4 (50 %) 10 (34 %) 0 (0 %) 4 (50 %) 18 (15 %)
Midazolam 3 (38 %) 5 (17 %) 0 (0 %) 3 (38 %) 11 (9 %)
Propofol 3 (38 %) 10 (34 %) 1 (33 %) 2 (25 %) 16 (13 %)
Morphine 1 (13 %) 16 (55 %) 2 (67 %) 4 (50 %) 23 (19 %)
Fentanyl 3 (38 %) 6 (21 %) 1 (33 %) 1 (13 %) 11 (9 %)
Number (%) for each sedative drug reflects use of more than 1 drug per patient
DNI do-not-intubate
Table 4 Baseline characteristics in non-do not intubate (DNI) and DNI groups
Non-DNI group (n = 39) DNI group (n = 81)
Intermittent (n = 28) Continuous (n = 11) P-value Intermittent (n = 44) Continuous (n= 37) P-value
Gender (male/female) 22/6 8/3 0.70 26/18 28/9 0.11
Age (y) 71.1 ± 10.9 60.5 ± 14.3 0.035 80.5 ± 8.1 74.9 ± 9.9 0.010
Duration of NIV (d) 4.5 ± 4.5 9.7 ± 11.7 0.044 7.0 ± 4.7 8.5 ± 5.3 0.12
Duration of continuous sedation (d) − 7.7 ± 12.0 − − 5.1 ± 3.2 −
Managing ward
general ward 6/28 (21 %) 2/11 (18 %) 0.82 18/44 (41 %) 9/37 (24 %) 0.11
emergency ward 17/28 (61 %) 7/11 (64 %) 0.87 23/44 (52 %) 21/37 (57 %) 0.69
ICU 5/28 (18 %) 2/11 (18 %) 0.98 3/44 (7 %) 7/37 (19 %) 0.10
Respiratory failure (without/with hypercapnia)a 18/5 9/1 0.42 14/28 23/11 0.003
P/F ratio (mmHg) 114 ± 49 108 ± 62 0.49 148 ± 80 111 ± 51 0.032
NIV setting (CPAP/ PSV) 15/13 7/4 0.57 13/31 11/26 0.99
P/F PaO2/FiO2, CPAP continuous positive airway pressure, PSV pressure support ventilation
a6 patients in non-DNI group and 5 in the DNI group did not undergo blood gas examination
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DNI patients could continue NIV with sedation. Overall,
115 of 120 (96 %) patients studied continued NIV despite
agitation.
Adverse events
As shown in Table 6, no patient vomited or developed
aspiration pneumonitis during NIV treatment. Among
the adverse events, 1 patient who had been prescribed
midazolam became hypotensive requiring dopamine, 1
patient experienced delirium, and 1 patient developed
ileus, which improved following the discontinuation of
sedatives. Three patients who had hypercapnia before
sedation exhibited drowsiness due to progressive hyper-
capnia, which improved following an increase in pres-
sure support levels. Before and after the start of
sedation, the RASS score, respiratory rate, heart rate,
and systolic blood pressure did not differ significantly
between intermittent and continuous use groups, nor
did acute changes occur during the 24 h from the start
of sedation (Additional file 1).
The values of arterial blood gas were rechecked within
24 h from the start of sedation in 18 patients in the
intermittent use group and 18 in the continuous use
group. Changes in PaCO2 levels were significantly
greater in the continuous use group than in the intermit-
tent use group (Fig. 2). There were no significant differ-
ences in changes in pH and P/F ratio between groups
(Additional file 2).
Discussion
Of 3506 patients with acute respiratory failure adminis-
tered NIV treatment in our institution, 120 (3.4 %) were
sedated to control agitation. Fifty-eight (48 %) of the 120
patients had diseases for which there was not a high de-
gree of evidence supporting NIV treatment such as
ARDS, ALI, severe pneumonia, or acute exacerbation of
interstitial pneumonia. However, no patient in the non-
DNI group being administered continuous sedation re-
quired intubation due to agitation, and 96 % of patients
in the DNI group were able to continue NIV treatment.
Therefore, in clinical practice, we effectively used sed-
ation to continue NIV in both DNI and non-DNI pa-
tients with management according to RASS scores.
However, as to continuous use, we must be aware of an
increased hypercapnic state and the possibility of in-
creased mortality.
In this study, we found that by using several sedatives
intermittently or continuously according to RASS scores,
the NIV failure rate due to agitation was quite low (4 %).
Table 5 Mortality rates and failure rates of sedation
Non-DNI group (n = 39) DNI group (n = 81)
Intermittent (n = 28) Continuous (n = 11) P-value Intermittent (n = 44) Continuous (n = 37) P-value
Mortality 6/28 (21 %) 1/11 (9 %) 0.37 25/44 (57 %) 30/37 (81 %) 0.020
Total intubation 8/28 (29 %) 3/11 (27 %) 0.94
Intubation due to agitation 2/28 (7 %)a 0/11 (0 %) 0.36
Discontinuation of NIV due to agitation 2/44 (5 %)b 1/37 (3 %)c 0.66
aincludes haloperidol in 2 patients
bincludes risperidone in 1, haloperidol in 1 patient
cincludes midazolam and morphine in 1 patient
Table 6 Adverse events during sedation
Intermittent (n = 72) Continuous (n = 48)
Oversedation haloperidol 1 midazolam 1, propofol 1
Hypotension morphine 1a, midazolam 1b
Delirium morphine 1
Ileus fentanyl 1
aimproved after discontinuation of sedatives
bneeded dopamine
Fig. 2 PaCO2 change within 24 h after initiation of each sedative.
Individual data and group means are represented. Data are shown
as mean ± standard deviation
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Previous studies have addressed the efficacy of sedation
during NIV using dexmedetomidine [6–8], midazolam
[8], propofol [9], and remifentanil [10] in patients with
several diseases in which there was a high-to-
intermediate level of evidence for NIV use. In addition,
these patients were treated in an ICU. In this study,
almost half of the patients had diseases with a low
evidence level supporting NIV treatment (ARDS/ALI/
severe pneumonia or acute exacerbation of interstitial
pneumonia), and despite this, almost all were man-
aged successfully with sedatives. Therefore, with the
guidance of RASS scores, proficient medical teams
for NIV treatment might control persistent agitation
with appropriate sedatives while administering NIV,
even in patients having diseases with poor evidence
of the usefulness of NIV.
In this study, patients were divided into two groups;
DNI and non-DNI groups. Although this resulted in a
small sample size for analysis in some groups, we
thought that differences in the usage of sedatives be-
tween DNI and non-DNI patients might be informative
to those managing NIV treatment with sedatives. When
NIV treatment is not effective in non-DNI patients,
physicians usually choose intubation with mechanical
ventilation. However, in DNI patients, intubation with
mechanical ventilation is not performed when NIV treat-
ment is not effective. That is, in the light of respiratory
management, failure to control agitation would become
fatal, and continuing NIV treatment with sedation is
critical in the DNI group. On the other hand, in the
non-DNI group, when we cannot continue NIV, we can
perform intubation and continue mechanical ventilation.
So in such cases we do not necessarily persist in con-
tinuing NIV treatment, and sedation is optional. In this
study, 9 (23 %) non-DNI patients were intubated for
reasons other than sedation insufficiency, such as ex-
acerbation of the respiratory status or hemodynamic
instability (Table 5). Therefore, especially in patients
with underlying diseases in which there is not strong
evidence for the effectiveness of NIV treatment, we
should avoid delaying intubation due to persistence
in administering sedatives during NIV in non-DNI
patients [14, 15].
Among DNI patients, only 2 patients (5 %) in the
intermittent use group and 1 patient (3 %) in the con-
tinuous use group discontinued NIV treatment, indicat-
ing that a high rate of persistence could be achieved
with sedation. However, we must note that 30-day mor-
tality in the DNI patients was higher in the continuous
use group than in the intermittent use group. In previ-
ous reports, mortality was reported to be 44–57 %
among DNI patients under NIV [16, 17] Also, among
those with hypoxemic respiratory failure, the mortality
rate of DNI patients was reported to be as high as 86 %
[18]. In Japan when a patient cannot make decisions we
usually provide NIV to those with a DNI status accord-
ing to the family’s will, even when the baseline status is
too poor for rescue or there is little evidence of NIV’s
usefulness for the background disease. Many patients in
the DNI group were severely ill and tended to become
agitated and need sedation. Therefore, we often had to
continue NIV with sedation as palliative care, which
might on one hand contribute in some degree to the
high mortality rate, and on the other hand contribute
to prolonging useless agony. To avoid the latter, we
discontinued NIV in DNI patients in accordance with
patient’s and/or family’s decision in cases of persist-
ent agitation. However, we must consider the possi-
bility that the continuous sedation itself increased
the mortality rate.
In this study, sedation during NIV treatment was in-
troduced to 31 % of the study patients in the general
wards, and in most of these patients treatment could be
continued in the general wards. Many members of the
medical staff of our hospital are highly experienced in
NIV treatment so that NIV with sedatives could be con-
trolled in general wards. However, as we did not have
data on a sufficient number of patients to make a defini-
tive conclusion on the safety of NIV treatment with sed-
atives, NIV treatment with sedatives should be applied
cautiously and at present should be performed in an
ICU.
As to complications, the change in the PaCO2 level
within 24 h after initiation of sedation was significantly
greater in the continuous use group than in the intermit-
tent use group. This difference would be mainly due to
the oversedated cases with hypercapnia, all of which had
hypercapnia before sedation. However, their condition
improved after increasing pressure support. Attention
must be paid to the possibility of severe complications
from continuous sedation such as hypotension or over-
sedation, especially in patients with hypercapnia prior to
the start of sedation.
Our study had several limitations. First, it was retro-
spective and there was substantial heterogeneity in
underlying diseases, sedation, therapies, and the seda-
tives used. However, the aim of this study was to clarify
the role of sedation during NIV treatment in clinical
practice, and we identified all consecutive patients using
NIV to minimize selection bias. Second, the sample size
was too small to detect significant differences. In
addition, we could not compare the efficacy of each
sedative or results according to each underlying disease
due to the small number of patients. However, we could
show the practical use of sedation during NIV treatment.
Third, we could not directly compare sedated patients to
unsedated patients who received NIV in the same study
period. This makes it difficult to examine the cause of
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the high mortality rate among sedated patients in the
DNI group. However, comparison with previous studies
could have helped to evaluate the present results. Fourth,
this study was conducted in a single institution that was
proficient in the use of NIV treatment; therefore, we have
to consider the indication for sedation because it depends
on the proficiency or system in each institution. In consid-
eration of these limitations, larger controlled studies are
needed to better clarify the role of sedation in improving
NIV outcomes in intolerant patients.
Conclusions
Our results suggest that sedation during NIV can be
used to enable continuation of NIV in agitated patients
with either a DNI or non-DNI status with management
according to RASS, even in patients with diseases for
which there is little evidence of the usefulness of NIV.
However, we must be aware of the possibility of an in-
creased hypercapnic state and high mortality rate associ-
ated with continuous sedation, which may be due to the
sedation itself. Also, continuing NIV under sedation is
not appropriate in cases of failure to control agitation
both in DNI patients in consideration of the risk of
prolonging distress and agony, and in non-DNI patients
considering the risk of unduly delaying intubation. In
addition, it should be taken into consideration about the
indication for sedation in each patient and the setting in
which it is provided (general wards or ICU) because
much depends on the proficiency or system in each
institution.
Additional files
Additional file 1: Changes in RASS score, respiratory rate, heart
rate, and systolic blood pressure before and after the start of
sedation. RASS, Richmond Agitation Sedation Scale.
Additional file 2: Changes in pH and P/F ratio within 24 h after
initiation of each sedative. P/F, PaO2/FiO2. *Comparison of change in
pH and PaO2/FiO2 ratio between intermittent and continuous use groups.
Abbreviations
NIV: Noninvasive ventilation; DNI: Do-not-intubate; RASS: Richmond Agitation
Sedation Scale; P/F: PaO2/FiO2; ARDS: Acute respiratory distress syndrome;
ALI: Acute lung injury.
Competing interests
KC belongs to The Department of Respiratory Care and Sleep Control
Medicine which is funded by endowments from Philips-Respironics, Teijin
Pharma, Fukuda Denshi, and Fukuda Lifetec Keiji to Kyoto University. The
other authors declare that they have no competing interests.
Authors’ contributions
TM contributed to the study design, collection of data, analysis and
interpretation of data, and writing the manuscript. KT, RT and KO
contributed to the study design, collection of data and editing the draft. KN,
KO and AN contributed to the study design and collection of data. MM
contributed to the study design and study supervision. KC contributed to the
study design and editing the draft. All authors read and approved the final
manuscript.
Acknowledgements
This work was supported in part by grants from the Japanese Ministry of
Education, Culture, Sports, Science and Technology, Respiratory Failure
Research Group from the Ministry of Health, Labor and Welfare of Japan, and
the Japan Vascular Disease Research Foundation.
Author details
1Department of Respiratory Medicine, Kobe City Medical Center General
Hospital, 2-1-1 Minatojima-minamimachi, Chuo-ku, Kobe 650-0047, Japan.
2Department of Respiratory Medicine, Graduate School of Medicine, Kyoto
University, 54 kawahara-cho, shogoin, sakyo-ku, Kyoto 606-8507, Japan.
3Department of Respiratory Care and Sleep Control Medicine, Graduate
School of Medicine, Kyoto University, 54 kawahara-cho, shogoin, sakyo-ku,
Kyoto 606-8507, Japan.
Received: 9 January 2015 Accepted: 6 July 2015
References
1. Antonelli M, Conti G, Moro ML, Esquinas A, Gonzalez-Diaz G, Confalonieri M,
et al. Predictors of failure of noninvasive positive pressure ventilation
in patients with acute hypoxemic respiratory failure: a multi-center
study. Intensive Care Med. 2001;27(11):1718–28.
2. Carlucci A, Richard JC, Wysocki M, Lepage E, Brochard L. Noninvasive versus
conventional mechanical ventilation. An epidemiologic survey. Am J Respir
Crit Care Med. 2001;163(4):874–80.
3. Nava S, Hill N. Non-invasive ventilation in acute respiratory failure. Lancet.
2009;374(9685):250–9.
4. Liesching T, Kwok H, Hill NS. Acute applications of noninvasive positive
pressure ventilation. Chest. 2003;124(2):699–713.
5. Devlin JW, Nava S, Fong JJ, Bahhady I, Hill NS. Survey of sedation practices
during noninvasive positive-pressure ventilation to treat acute respiratory
failure. Crit Care Med. 2007;35(10):2298–302.
6. Akada S, Takeda S, Yoshida Y, Nakazato K, Mori M, Hongo T, et al. The
efficacy of dexmedetomidine in patients with noninvasive ventilation: a
preliminary study. Anesth Analg. 2008;107(1):167–70.
7. Takasaki Y, Kido T, Semba K. Dexmedetomidine facilitates induction of
noninvasive positive pressure ventilation for acute respiratory failure in
patients with severe asthma. J Anesth. 2009;23(1):147–50.
8. Huang Z, Chen YS, Yang ZL, Liu JY. Dexmedetomidine versus midazolam for
the sedation of patients with non-invasive ventilation failure. Intern Med.
2012;51(17):2299–305.
9. Clouzeau B, Bui HN, Vargas F, Grenouillet-Delacre M, Guilhon E, Gruson D, et
al. Target-controlled infusion of propofol for sedation in patients with non-
invasive ventilation failure due to low tolerance: a preliminary study.
Intensive Care Med. 2010;36(10):1675–80.
10. Rocco M, Conti G, Alessandri E, Morelli A, Spadetta G, Laderchi A, et al.
Rescue treatment for noninvasive ventilation failure due to interface
intolerance with remifentanil analgosedation: a pilot study. Intensive Care
Med. 2010;36(12):2060–5.
11. Tomii K, Tachikawa R, Chin K, Murase K, Handa T, Mishima M, et al. Role of
non-invasive ventilation in managing life-threatening acute exacerbation of
interstitial pneumonia. Intern Med. 2010;49(14):1341–7.
12. Murase K, Tomii K, Chin K, Tsuboi T, Sakurai A, Tachikawa R, et al. The use of
non-invasive ventilation for life-threatening asthma attacks: Changes in the
need for intubation. Respirology. 2010;15(4):714–20.
13. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, et
al. The Richmond Agitation-Sedation Scale: validity and reliability in
adult intensive care unit patients. Am J Respir Crit Care Med.
2002;166(10):1338–44.
14. Esteban A, Frutos-Vivar F, Ferguson ND, Arabi Y, Apezteguia C, Gonzalez M,
et al. Noninvasive positive-pressure ventilation for respiratory failure after
extubation. N Engl J Med. 2004;350(24):2452–60.
15. Merlani PG, Pasquina P, Granier JM, Treggiari M, Rutschmann O,
Ricou B. Factors associated with failure of noninvasive positive
pressure ventilation in the emergency department. Acad Emerg Med.
2005;12(12):1206–15.
16. Levy M, Tanios MA, Nelson D, Short K, Senechia A, Vespia J, et al. Outcomes
of patients with do-not-intubate orders treated with noninvasive ventilation.
Crit Care Med. 2004;32(10):2002–7.
Matsumoto et al. BMC Pulmonary Medicine  (2015) 15:71 Page 8 of 9
17. Azoulay E, Kouatchet A, Jaber S, Lambert J, Meziani F, Schmidt M, et al.
Noninvasive mechanical ventilation in patients having declined tracheal
intubation. Intensive Care Med. 2013;39(2):292–301.
18. Schettino G, Altobelli N, Kacmarek RM. Noninvasive positive pressure
ventilation reverses acute respiratory failure in select "do-not-intubate"
patients. Crit Care Med. 2005;33(9):1976–82.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Matsumoto et al. BMC Pulmonary Medicine  (2015) 15:71 Page 9 of 9
